Vimarsana
Biggest News Aggregation in the World

Nasdaq Gbt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Gbt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Gbt Today - Breaking & Trending Today

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Expected to Earn FY2022 Earnings of ($4.55) Per Share - Vimarsana News

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Expected to Earn FY2022 Earnings of ($4.55) Per Share

Published: September 24, 2022

Global Blood Therapeutics, Inc. (NASDAQ:GBT – Get Rating) – Investment analysts at Cantor Fitzgerald issued their FY2022 earnings estimates for Global Blood Therapeutics in a research report issued on Wednesday, September 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($4.55) per share for the year. Cantor Fitzgerald currently has a “Neutral” […]

Source: etfdailynews.com
Related Topics:
United StatesNazila HabibizadStifel NicolausWilliam BlairSecurities Exchange CommissionEnsign Peak Advisors IncGlobal Blood Therapeutics IncCantor FitzgeraldAdvisor Group Holdings IncCanaccord Genuity GroupDimensional Fund AdvisorsGlobal Blood TherapeuticsGet RatingGlobal Blood TherapeuticGenuity GroupTruist FinancialBlood TherapeuticsGlobal BloodGroup HoldingsFund AdvisorsRetirement SystemPeak Advisors IncExchange CommissionGlobal Blood Therapeutics DailyNasdaq Gbt
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022 - Vimarsana News

These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022

Published: September 20, 2022

Investing in mid-cap stocks is essential for investors who prefer a diversified portfolio. These stocks offer a middle ground with regard to the risks

Source: marketbeat.com
Related Topics:
New YorkUnited StatesSan DiegoSouth San FranciscoSan CarlosSanta ClaraMultiplan CorpCompanies Mentioned In This ArticleTandem Diabetes Care IncAxsome Therapeutics IncGetty Images HoldingsGlobal Blood Therapeutics IncKaruna Therapeutics IncSitime CorpGetty Images Holdings IncSpacemobile IncNovavax IncChemocentryx IncBest Performing Mid Cap Stocks In AugustNew York CityTherapeutics IncAxsome TherapeuticsMobile IncKaruna TherapeuticsBlood Therapeutics
GBT and Sickle Cell Disease Association of America to Host - Vimarsana News

GBT and Sickle Cell Disease Association of America to Host

Published: September 8, 2022

Keynote by Admiral Rachel Levine, M.D., Assistant Secretary for Health, U.S. Department of Health and Human Services...

Source: globenewswire.com
Related Topics:
United StatesAmerican Red CrossSouth CarolinaUniversity Of South CarolinaBiree AndemariamMarsha TreadwellKim Smith WhitleySteven ImmergutRebecca RobbinsLewis HsuCourtney RobertsDiretrizes TerapBa Stephanie GeorgeRichard DrachtmanRegina HartfieldRachel LevineChris Van HollenAlan AndersonRonisha Edwards ElliotAyanal JohnsonHermionne JohnsonJennifer GeorgeKyri JacobsNational Sickle Cell Awareness MonthPrisma Health
The GBT Foundation Awards $250,000 in ACE Grants to Support - Vimarsana News

The GBT Foundation Awards $250,000 in ACE Grants to Support

Published: July 13, 2022

SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood...

Source: globenewswire.com
Related Topics:
United StatesSan DiegoSteven ImmergutDiretrizes TerapJunge ChoiSickle Cell Advocacy Project Inc MiamiSickle Cell Warriors Advocacy Training Empowerment ProgramChildren Sickle Cell Foundation Inc PittsburghMaryland Sickle Cell Disease Association BaltimoreSickle Cell Family Leadership ProgramSickle Cell Association Of South Louisiana LafayetteGrant ProgramBlood InstituteNational HeartCenters For DiseaseSickle Cell Warriors IncGlobal Blood Therapeutics IncSickle ProgramEuropean Medicines AgencyGlobal Blood TherapeuticsCare EmpowermentSickle CellSickle Cell Advocacy ProjectSickle Cell FoundationLiving Well
GBT's Inclacumab and GBT601 Receive U.S. FDA Orphan Drug - Vimarsana News

GBT's Inclacumab and GBT601 Receive U.S. FDA Orphan Drug

Published: June 6, 2022

Inclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive crises (VOCs) and readmissions due to VOCs in...

Source: globenewswire.com
Related Topics:
United StatesKim Smith WhitleyDrug AdministrationGlobal Blood Therapeutics IncBlood TherapeuticsSouth AsianSouthern EuropeanMiddle EasternNasdaq GbtGlobal Blood Therapeutics